staurosporine has been researched along with semaxinib in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daniels, RN; Gentry, PR; Hao, J; Ho, JN; Hong, CC; Hopkins, CR; Karim, KA; Lewis, JA; Lindsley, CW | 1 |
| Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A | 1 |
| Bocci, G; Cosconati, S; D'Ocon, P; Da Settimo, F; Dalla Via, L; Fioravanti, A; Fornaciari, G; García-Argáez, AN; Gia, O; La Motta, C; Marini, AM; Novellino, E; Orlandi, P; Salerno, S; Sartini, S; Simorini, F; Taliani, S | 1 |
| Amendola, G; Barresi, E; Cosconati, S; Da Settimo, F; García-Argáez, AN; La Motta, C; Marini, AM; Novellino, E; Salerno, S; Simorini, F; Taliani, S; Tomassi, S; Via, LD | 1 |
| Berdel, WE; Müller-Tidow, C; Serve, H; Tickenbrock, L | 1 |
| Fiedler, W; Wellbrock, J | 1 |
2 review(s) available for staurosporine and semaxinib
| Article | Year |
|---|---|
Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
Topics: Animals; Antineoplastic Agents; Carbazoles; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Staurosporine | 2006 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
4 other study(ies) available for staurosporine and semaxinib
| Article | Year |
|---|---|
In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.
Topics: Animals; Bone Morphogenetic Proteins; Drug Evaluation, Preclinical; Embryo, Nonmammalian; Pyrazoles; Pyrimidines; Quinolines; Structure-Activity Relationship; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Zebrafish | 2010 |
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase | 2013 |
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Human Umbilical Vein Endothelial Cells; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrans; Pyrimidines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Human Umbilical Vein Endothelial Cells; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrans; Pyrimidines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2018 |